The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver
Official Title: Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver
Study ID: NCT01686880
Brief Summary: The purpose of this study is to assess the safety of transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma
Detailed Description: The purpose of this study is to assess the peri-operative morbidity and mortality of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Institut Jules Bordet, Brussels, , Belgium
Erasme Hosptial, Brussels, , Belgium
Name: Alain Hendlisz, MD
Affiliation: Jules Bordet Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Vincent Donckier, MD, PHD
Affiliation: Erasme University Hospital
Role: PRINCIPAL_INVESTIGATOR